Media headlines about Opexa Therapeutics (NASDAQ:ACER) have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Opexa Therapeutics earned a news impact score of 0.01 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 44.8538482483994 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Opexa Therapeutics (NASDAQ ACER) opened at $16.36 on Friday. Opexa Therapeutics has a 1-year low of $5.69 and a 1-year high of $22.63. The stock has a market cap of $116.48, a price-to-earnings ratio of -2.85 and a beta of 2.24.
Opexa Therapeutics (NASDAQ:ACER) last issued its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter. equities analysts anticipate that Opexa Therapeutics will post -1.48 earnings per share for the current year.
WARNING: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3126849/opexa-therapeutics-acer-getting-somewhat-positive-media-coverage-report-finds.html.
Opexa Therapeutics Company Profile
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Opexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.